Holen Sie sich die Stockscreener-App
8.59
0.94%
0.08
Schlusskurs vom Vortag:
$8.51
Offen:
$8.5
24-Stunden-Volumen:
25,100
Relative Volume:
0.67
Marktkapitalisierung:
$48.80M
Einnahmen:
$43.77M
Nettoeinkommen (Verlust:
$-35.04M
KGV:
-2.6414
EPS:
-3.2521
Netto-Cashflow:
$-5.51M
1W Leistung:
+4.31%
1M Leistung:
+15.77%
6M Leistung:
-25.59%
1J Leistung:
-9.73%
1-Tages-Spanne:
$8.44
$9.1999
1-Wochen-Bereich:
$8.20
$9.1999
52-Wochen-Spanne:
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.44 | 49.21M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Surprises Report: How cyclical is Xilio Therapeutics Incs revenue streamQuarterly Investment Review & Real-Time Stock Entry Alerts - baoquankhu1.vn
XLO Should I Buy - Intellectia AI
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Xilio Therapeutics, Inc. (XLO) stock price, news, quote and history - Yahoo Finance UK
Xilio Therapeutics Announces Inducement Grants - National Today
Xilio Therapeutics Grants Inducement Shares Under Nasdaq Rule - National Today
Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan
XLO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Xilio Therapeutics (XLO) Raised to Buy: How Will This Impact the Shares? - Bitget
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Update Report: Does Xilio Therapeutics Inc have high return on assets2026 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
Retail Trends: Can Xilio Therapeutics Inc deliver alphaMarket Sentiment Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares - Investing.com
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares By Investing.com - Investing.com India
Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy - MarketBeat
Retail Trends: Can Xilio Therapeutics Inc expand into new marketsWeekly Stock Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Market Catalysts: How much upside does Xilio Therapeutics Inc have2026 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Xilio plans mid-2026 IND filing for cancer therapy XTX501 By Investing.com - Investing.com Australia
Xilio Therapeutics Extends Cash Runway Through 2027 and Advances Masked Immuno-Oncology Pipeline, Including XTX501 and Multi-Specific T Cell Engagers 123 - Minichart
Xilio Therapeutics: Advancing Masked Immuno-Oncology Therapies for Improved Cancer Outcomes - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xilio plans mid-2026 IND filing for cancer therapy XTX501 - Investing.com
Xilio Therapeutics 2025 10-K: Revenue $43.8M, EPS (loss) $0.00 - TradingView
Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan
XLO: Collaboration revenue surged and cash runway extended as pipeline advanced toward key milestones - TradingView
Xilio (NASDAQ: XLO) boosts 2025 revenue and cash runway into 2027 - Stock Titan
BRIEF-Xilio Therapeutics Q4 Net Income USD 10.36 Million - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Xilio Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan
Volume Summary: Can Xilio Therapeutics Inc deliver alphaWeekly Stock Summary & Daily Entry Point Alerts - baoquankhu1.vn
Trading Recap: What is the long term forecast for Xilio Therapeutics Inc stockGold Moves & Community Consensus Picks - baoquankhu1.vn
Can Xilio Therapeutics Inc sustain earnings growthWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Exit Recap: Will Boyd Gaming Corporation stock benefit from M A2026 EndofMonth & Weekly Return Optimization Plans - baoquankhu1.vn
XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com Australia
Xilio Therapeutics to present data on masked cancer therapy at AACR By Investing.com - Investing.com South Africa
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - marketbeat.com
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Bitget
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com Canada
Xilio Therapeutics announces 1-for-14 reverse stock split - MSN
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - Sahm
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xilio Therapeutics Inc-Aktie (XLO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 16 '25 |
Buy |
0.69 |
45,000 |
30,870 |
45,000 |
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):